Showing results (31-40 of 46) with videos related to
Sort By:
Pageof 5
Lancet (London, England)|September 19, 2006
Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serumDan Agranoff, Delmiro Fernandez-Reyes, Marios C Papadopoulos, et al.Journal of Crohn'S & Colitis|December 7, 2017
Exome Sequencing and Genotyping Identify a Rare Variant in NLRP7 Gene Associated With Ulcerative ColitisAlexandros Onoufriadis, Kristina Stone, Antreas Katsiamides, et al.Trials|August 4, 2021
Supported online self-management versus care as usual for symptoms of fatigue, pain and urgency/incontinence in adults with inflammatory bowel disease (IBD-BOOST): study protocol for a randomised controlled trialChristine Norton, Jonathan Syred, Sally Kerry, et al.Alimentary Pharmacology & Therapeutics|October 10, 2019
Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patientsChristian P Selinger, Gareth C Parkes, Ash Bassi, et al.The Lancet. Digital Health|November 8, 2025
Digital cognitive behavioural self-management programme for fatigue, pain, and faecal incontinence in inflammatory bowel disease (IBD-BOOST): a multicentre, parallel, randomised controlled trialRona Moss-Morris, Christine Norton, Ailsa Hart, et al.Frontline Gastroenterology|October 19, 2023
Opioid use and associated factors in 1676 patients with inflammatory bowel disease: a multicentre quality improvement projectSamantha Baillie, Jimmy K Limdi, Ash Bassi, et al.The Lancet. Gastroenterology & Hepatology|January 14, 2023
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trialEdouard Louis, Matthieu Resche-Rigon, David Laharie, et al.Frontline Gastroenterology|September 3, 2020
Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemicNicholas A Kennedy, Richard Hansen, Lisa Younge, et al.Health Technology Assessment (Winchester, England)|October 19, 2021
A high-dose 24-hour tranexamic acid infusion for the treatment of significant gastrointestinal bleeding: HALT-IT RCTIan Roberts, Haleema Shakur-Still, Adefemi Afolabi, et al.Plos Genetics|February 12, 2015
Pooled sequencing of 531 genes in inflammatory bowel disease identifies an associated rare variant in BTNL2 and implicates other immune related genesNatalie J Prescott, Benjamin Lehne, Kristina Stone, et al.Pageof 5